Overview

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
JNJ-42165279